Xtandi 80 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FJQC6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,255
Award facts
- Contract value 100% obligated
- $4,255.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $4,255.34 to DMS Pharmaceutical Group Inc. for 60 tablets of Xtandi 80 mg, an oncology medication used in prostate cancer treatment. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded this firm fixed-price delivery order on January 30, 2026, with an ultimate completion date of February 2, 2026. The contract carries no set-aside designation, indicating the award was made through unrestricted federal procurement competition.
This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. DMS Pharmaceutical Group holds a single-award IDC valued at $499,999,999 through December 31, 2036, authorizing DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. The company's established performance across numerous prior delivery orders demonstrates its capability to fulfill specialized pharmaceutical requirements within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FJQC6?
SPE2DR26FJQC6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FJQC6 worth?
The government has obligated $4,255 on SPE2DR26FJQC6.
Is contract SPE2DR26FJQC6 an order under another contract?
Yes. SPE2DR26FJQC6 is a delivery order under SPE2DR25D9224, an indefinite delivery contract.
Was contract SPE2DR26FJQC6 competed?
The extent of competition for SPE2DR26FJQC6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award